Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- association label "rizatriptan benzoate tablets are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old information related to usage of rizatriptan benzoate in pediatric patients 6 to 17 years old is approved for merck co inc s rizatriptan benzoate tablets however due to merck co inc s marketing exclusivity rights this drug product is not labeled with that pediatric patient 6 to 17 years old usage information limitations of use rizatriptan benzoate tablets should only be used where a clear diagnosis of migraine has been established if a patient has no response for the first migraine attack treated with rizatriptan benzoate tablets the diagnosis of migraine should be reconsidered before rizatriptan benzoate tablets is administered to treat any subsequent attacks rizatriptan benzoate tablets are not indicated for use in the management of hemiplegic or basilar migraine see contraindications 4 rizatriptan benzoate tablets are not indicated for the prevention of migraine attacks safety and effectiveness of rizatriptan benzoate tablets have not been established for cluster headache rizatriptan benzoate tablets are a serotonin 5 ht 1b 1d receptor agonist triptan indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years of age 1 limitations of use use only after clear diagnosis of migraine has been established 1 not indicated for the prophylactic therapy of migraine 1 not indicated for the treatment of cluster headache 1" assertion.
- association label "doxycycline hyclate tablets are tetracycline class drugs indicated for rickettsial infections 1 1 sexually transmitted infections 1 2 respiratory tract infections 1 3 specific bacterial infections 1 4 ophthalmic infections 1 5 anthrax including inhalational anthrax post exposure 1 6 alternative treatment for selected infections when penicillin is contraindicated 1 7 adjunctive therapy for acute intestinal amebiasis and severe acne 1 8 prophylaxis of malaria 1 9 to reduce the development of drug resistant bacteria and maintain the effectiveness of doxycycline hyclate tablets and other antibacterial drugs doxycycline hyclate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria 1 1 doxycycline hyclate tablets are indicated for treatment of rocky mountain spotted fever typhus fever and the typhus group q fever rickettsial pox and tick fevers caused by rickettsiae doxycycline hyclate tablets are indicated for treatment of the following sexually transmitted infections uncomplicated urethral endocervical or rectal infections caused by chlamydia trachomatis nongonococcal urethritis caused by ureaplasma urealyticum lymphogranuloma venereum caused by chlamydia trachomatis granuloma inguinale caused by klebsiella granulomatis uncomplicated gonorrhea caused by neisseria gonorrhoeae chancroid caused by haemophilus ducreyi doxycycline hyclate tablets are indicated for treatment of the following respiratory tract infections respiratory tract infections caused by mycoplasma pneumoniae psittacosis ornithosis caused by chlamydophila psittaci because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline culture and susceptibility testing are recommended doxycycline is indicated for treatment of infections caused by the following microorganisms when bacteriological testing indicates appropriate susceptibility to the drug respiratory tract infections caused by haemophilus influenzae respiratory tract infections caused by klebsiella species upper respiratory infections caused by streptococcus pneumoniae doxycycline hyclate tablets are indicated for treatment of the following specific bacterial infections relapsing fever due to borrelia recurrentis plague due to yersinia pestis tularemia due to francisella tularensis cholera caused by vibrio cholerae campylobacter fetus infections caused by campylobacter fetus brucellosis due to brucella bartonellosis due to bartonella bacilliformis because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline culture and susceptibility testing are recommended doxycycline hyclate tablets are indicated for treatment of infections caused by the following gram negative microorganisms when bacteriological testing indicates appropriate susceptibility to the drug escherichia coli enterobacter aerogenes shigella acinetobacter urinary tract infections caused by klebsiella doxycycline hyclate tablets are indicated for treatment of the following ophthalmic infections trachoma caused by chlamydia trachomatis inclusion conjunctivitis caused by chlamydia trachomatis doxycycline hyclate tablets are indicated for the treatment of anthrax due to bacillus anthracis bacillus anthracis doxycycline hyclate tablets are indicted as an alternative treatment for the following selected infections when penicillin is contraindicated syphilis caused by treponema pallidum yaws caused by treponema pallidum pertenue listeriosis due to listeria monocytogenes vincent s infection caused by fusobacterium fusiforme actinomycosis caused by actinomyces israelii infections caused by clostridium in acute intestinal amebiasis doxycycline hyclate tablets may be a useful adjunct to amebicides in severe acne doxycycline hyclate tablets may be useful adjunctive therapy doxycycline hyclate tablets are indicated for the prophylaxis of malaria due to plasmodium falciparum see dosage and administration 2 4 patient counseling information 17 to reduce the development of drug resistant bacteria and maintain the effectiveness of doxycycline hyclate tablets and other antibacterial drugs doxycycline hyclate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy" assertion.
- association label "fluvoxamine maleate extended release capsules are a selective serotonin reuptake inhibitor ssri indicated for the treatment of obsessive compulsive disorder ocd 1 one 12 week study with fluvoxamine maleate extended release capsules in adults 14 1 two 1 week studies with immediate release ir fluvoxamine tablets in adults and one 1 week study with ir fluvoxamine tablets in children and adolescents 14 1 14 3 one maintenance study with ir fluvoxamine tablets 14 2 fluvoxamine maleate extended release capsules are indicated for the treatment of obsessive compulsive disorder ocd as defined in the dsm iv obsessive compulsive disorder is characterized by recurrent and persistent ideas thoughts impulses or images obsessions that are ego dystonic and or repetitive purposeful and intentional behaviors compulsions that are recognized by the person as excessive or unreasonable the obsessions or compulsions cause marked distress are time consuming or significantly interfere with social or occupational functioning the efficacy of fluvoxamine maleate extended release capsules was demonstrated in one 12 week trial in adults with fluvoxamine maleate extended release capsules as well as in two 1 week trials in adults and in one 1 week trial in children and adolescents ages 8 to 17 years with immediate release fluvoxamine tablets in outpatients with the diagnosis of ocd as defined in dsm iv or dsm iii r see clinical studies 14 1 14 3 the efficacy of fluvoxamine for long term use was established in one maintenance study in adults with immediate release fluvoxamine tablets see clinical studies 14 2 see dosage and administration 2 4" assertion.
- association label "when oral therapy is not feasible and the strength dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition the intramuscular use of methylprednisolone acetate injectable suspension usp is indicated as follows control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions seasonal or perennial allergic rhinitis serum sickness transfusion reactions bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus severe erythema multiforme stevens johnson syndrome primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the drug of choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditis to tide the patient over a critical period of the disease in regional enteritis systemic therapy ulcerative colitis acquired autoimmune hemolytic anemia congenital erythroid hypoplastic anemia diamond blackfan anemia pure red cell aplasia select cases of secondary thrombocytopenia trichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy for palliative management of leukemias and lymphomas acute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor or craniotomy sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids to induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus berylliosis symptomatic sarcoidosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosis as adjunctive therapy for short term administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require low dose maintenance therapy for the treatment of dermatomyositis polymyositis and systemic lupus erythematosus see warnings methylprednisolone acetate injectable suspension usp is indicated as adjunctive therapy for short term administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis synovitis of osteoarthritis methylprednisolone acetate injectable suspension usp is indicated for intralesional use in alopecia areata discoid lupus erythematosus keloids localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus neurodermatitis and psoriatic plaques necrobiosis lipoidica diabeticorum methylprednisolone acetate injectable suspension usp also may be useful in cystic tumors of an aponeurosis or tendon ganglia" assertion.
- association label "venlafaxine hydrochloride extended release capsules usp are indicated for the treatment of major depressive disorder the efficacy of venlafaxine hydrochloride extended release capsules usp in the treatment of major depressive disorder was established in 8 and 12 week controlled trials of adult outpatients whose diagnoses corresponded most closely to the dsm iii r or dsm iv category of major depressive disorder see clinical trials a major depressive episode dsm iv implies a prominent and relatively persistent nearly every day for at least 2 weeks depressed mood or the loss of interest or pleasure in nearly all activities representing a change from previous functioning and includes the presence of at least five of the following nine symptoms during the same two week period depressed mood markedly diminished interest or pleasure in usual activities significant change in weight and or appetite insomnia or hypersomnia psychomotor agitation or retardation increased fatigue feelings of guilt or worthlessness slowed thinking or impaired concentration a suicide attempt or suicidal ideation the efficacy of venlafaxine hydrochloride tablets in the treatment of major depressive disorder in adult inpatients meeting diagnostic criteria for major depressive disorder with melancholia was established in a 4 week controlled trial see the safety and efficacy of venlafaxine hydrochloride extended release capsules usp in hospitalized depressed patients have not been adequately studied clinical trials the efficacy of venlafaxine hydrochloride extended release capsules usp in maintaining a response in major depressive disorder for up to 26 weeks following 8 weeks of acute treatment was demonstrated in a placebo controlled trial the efficacy of venlafaxine hydrochloride tablets in maintaining a response in patients with recurrent major depressive disorder who had responded and continued to be improved during an initial 26 weeks of treatment and were then followed for a period of up to 52 weeks was demonstrated in a second placebo controlled trial see nevertheless the physician who elects to use venlafaxine hydrochloride tablets venlafaxine hydrochloride extended release capsules usp for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient see clinical trials dosage and administration social anxiety disorder venlafaxine hydrochloride extended release capsules usp are indicated for the treatment of social anxiety disorder also known as social phobia as defined in dsm iv 3 23 social anxiety disorder dsm iv is characterized by a marked and persistent fear of 1 or more social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others exposure to the feared situation almost invariably provokes anxiety which may approach the intensity of a panic attack the feared situations are avoided or endured with intense anxiety or distress the avoidance anxious anticipation or distress in the feared situation s interferes significantly with the person s normal routine occupational or academic functioning or social activities or relationships or there is a marked distress about having the phobias lesser degrees of performance anxiety or shyness generally do not require psychopharmacological treatment the efficacy of venlafaxine hydrochloride extended release capsules usp in the treatment of social anxiety disorder was established in four 12 week and one 6 month placebocontrolled trials in adult outpatients with social anxiety disorder dsm iv see clinical trials although the effectiveness of venlafaxine hydrochloride extended release capsules usp has been demonstrated in a 6 month clinical trial in patients with social anxiety disorder the physician who elects to use venlafaxine hydrochloride extended release capsules usp for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient see dosage and administration panic disorder venlafaxine hydrochloride extended release capsules usp are indicated for the treatment of panic disorder with or without agoraphobia as defined in dsm iv panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks worry about the implications or consequences of the attacks and or a significant change in behavior related to the attacks panic disorder dsm iv is characterized by recurrent unexpected panic attacks ie a discrete period of intense fear or discomfort in which four or more of the following symptoms develop abruptly and reach a peak within 1 minutes 1 palpitations pounding heart or accelerated heart rate 2 sweating 3 trembling or shaking 4 sensations of shortness of breath or smothering 5 feeling of choking 6 chest pain or discomfort 7 nausea or abdominal distress 8 feeling dizzy unsteady lightheaded or faint 9 derealization feelings of unreality or depersonalization being detached from oneself 1 fear of losing control 11 fear of dying 12 paresthesias numbness or tingling sensations 13 chills or hot flushes the efficacy of venlafaxine hydrochloride extended release capsules usp in the treatment of panic disorder was established in two 12 week placebo controlled trials in adult outpatients with panic disorder dsm iv the efficacy of venlafaxine hydrochloride extended release capsules usp in prolonging time to relapse in panic disorder among responders following 12 weeks of open label acute treatment was demonstrated in a placebo controlled study see clinical pharmacology clinical trials nevertheless the physician who elects to use venlafaxine hydrochloride extended release capsules usp for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient see dosage and administration" assertion.
- association label "to reduce the development of drug resistant bacteria and maintain the effectiveness of penicillin g procaine and other antibacterial drugs penicillin g procaine should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy penicillin g procaine is indicated in the treatment of moderately severe infections in both adults and pediatric patients due to penicillin g susceptible microorganisms that are susceptible to the low and persistent serum levels common to this particular dosage form in the indications listed below therapy should be guided by bacteriological studies including susceptibility tests and by clinical response note when high sustained serum levels are required aqueous penicillin g either im or iv should be used the following infections will usually respond to adequate dosages of intramuscular penicillin g procaine moderately severe to severe infections of the upper respiratory tract skin and soft tissue infections scarlet fever and erysipelas due to susceptible streptococci group a without bacteremia note streptococci in groups a c g h l and m are very sensitive to penicillin g other groups including group d enterococcus are resistant aqueous penicillin is recommended for streptococcal infections with bacteremia moderately severe infections of the respiratory tract due to susceptible pneumococci note severe pneumonia empyema bacteremia pericarditis meningitis peritonitis and arthritis of pneumococcal etiology are better treated with aqueous penicillin g during the acute stage moderately severe infections of the skin and soft tissues due to susceptible staphylococci penicillin g susceptible note reports indicate an increasing number of strains of staphylococci resistant to penicillin g emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections indicated surgical procedures should be performed fusospirochetosis vincent s gingivitis and pharyngitis moderately severe infections of the oropharynx due to susceptible fusiform bacilli and spirochetes note necessary dental care should be accomplished in infections involving the gum tissue syphilis all stages due to susceptible treponema pallidum note this drug should not be used in the treatment of beta lactamase producing organisms which include most strains of neisseria gonorrhea yaws bejel pinta due to susceptible organisms penicillin g procaine is an adjunct to antitoxin for prevention of the carrier stage of diphtheria due to susceptible c diphtheriae anthrax due to bacillus anthracis bacillus anthracis rat bite fever due to susceptible streptobacillus moniliformis spirillum minus erysipeloid due to susceptible erysipelothrix rhusiopathia subacute bacterial endocarditis only in extremely sensitive infections due to susceptible group a streptococci" assertion.
- association label "saphris is indicated for schizophrenia in adults see clinical studies 14 1 bipolar i disorder see clinical studies 14 2 acute monotherapy of manic or mixed episodes in adults and pediatric patients 1 to 17 years of age adjunctive treatment to lithium or valproate in adults maintenance monotherapy treatment in adults saphris is an atypical antipsychotic indicated for 1 schizophrenia in adults bipolar i disorder acute monotherapy treatment of manic or mixed episodes in adults and pediatric patients 1 to 17 years of age adjunctive treatment to lithium or valproate in adults maintenance monotherapy treatment in adults" assertion.
- out1 label "out1" assertion.
- img label "img" assertion.
- step label "Add two numbers together" assertion.
- out1 label "out1" assertion.
- a label "a" assertion.
- b label "b" assertion.
- LinguisticSystem label "python" assertion.
- b label "b" assertion.
- a label "a" assertion.
- LinguisticSystem label "python" assertion.
- out1 label "out1" assertion.
- step label "Multiply two numbers together" assertion.
- out1 label "out1" assertion.
- img label "img" assertion.
- step label "Convert the image" assertion.
- LinguisticSystem label "python" assertion.
- out1 label "out1" assertion.
- img label "img" assertion.
- img label "img" assertion.
- out1 label "out1" assertion.
- image label "image" assertion.
- LinguisticSystem label "python" assertion.
- ratio label "ratio" assertion.
- step label "contrast image by factor" assertion.
- out1 label "out1" assertion.
- out1 label "out1" assertion.
- im1 label "im1" assertion.
- im2 label "im2" assertion.
- out1 label "out1" assertion.
- im1 label "im1" assertion.
- im2 label "im2" assertion.
- step label "Make white background of image transparent" assertion.
- out1 label "out1" assertion.
- img label "img" assertion.
- LinguisticSystem label "python" assertion.
- step label "Overlay image with another (partly transparent) one" assertion.
- out1 label "out1" assertion.
- bg_img label "bg_img" assertion.
- LinguisticSystem label "python" assertion.
- fg_img label "fg_img" assertion.
- img label "img" assertion.
- out1 label "out1" assertion.
- out1 label "out1" assertion.
- LinguisticSystem label "python" assertion.
- image label "image" assertion.
- step label "Put here a name of your awesome step (include the word awesome so others will find it)" assertion.
- image label "image" assertion.
- out1 label "out1" assertion.
- image label "image" assertion.
- out1 label "out1" assertion.
- LinguisticSystem label "python" assertion.
- step label "Convert image to grayscale" assertion.
- LinguisticSystem label "python" assertion.
- out1 label "out1" assertion.
- step label "Add blur to image" assertion.
- img label "img" assertion.
- ratio label "ratio" assertion.
- image label "image" assertion.
- out1 label "out1" assertion.
- step label "contrast image by factor" assertion.
- LinguisticSystem label "python" assertion.
- image label "image" assertion.
- out1 label "out1" assertion.
- out1 label "out1" assertion.
- img label "img" assertion.
- image label "image" assertion.
- out1 label "out1" assertion.
- ratio label "ratio" assertion.
- img label "img" assertion.
- LinguisticSystem label "python" assertion.
- out1 label "out1" assertion.
- step label "Make white background of image transparent" assertion.
- out1 label "out1" assertion.
- fg_img label "fg_img" assertion.
- LinguisticSystem label "python" assertion.
- bg_img label "bg_img" assertion.
- step label "Overlay image with another (partly transparent) one" assertion.
- LinguisticSystem label "python" assertion.
- plan label "awesome image maker" assertion.
- rate label "rate" assertion.
- step label "awesome step to pixelize an image, with adjustable rate" assertion.
- img label "img" assertion.
- out1 label "out1" assertion.
- LinguisticSystem label "python" assertion.
- step label "awesome step to pixelize an image, with adjustable rate" assertion.
- out1 label "out1" assertion.
- img label "img" assertion.
- LinguisticSystem label "python" assertion.
- rate label "rate" assertion.
- out1 label "out1" assertion.
- image label "image" assertion.
- step label "Invert the grayscale image to get a negative" assertion.
- out1 label "out1" assertion.